Maryland Will Require Insurers To Pay for Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

BALTIMORE, Md--The Maryland legislation has passed an historic bill requiring insurers, including managed care companies, to pay the patient care costs for patients enrolled in clinical trials. The law takes effect January 1999.

BALTIMORE, Md--The Maryland legislation has passed an historic bill requiring insurers, including managed care companies, to pay the patient care costs for patients enrolled in clinical trials. The law takes effect January 1999.

The legislation, sponsored by Senator Thomas Bromwell and Delegate Carolyn Krysiak, won the cooperation of the insurance industry, academic medical centers, and community physicians, as well as patient advocates.

"There is no doubt that clinical trials lead to better ways of preventing, diagnosing, and treating diseases such as cancer," said Martin D. Abeloff, MD, director of the Johns Hopkins Oncology Center.

Dr. Abeloff spoke to both the Maryland Senate Finance Committee and the House Economic Matters Committee about the proposed clinical trials legislation earlier this year.

The support of insurers came after an extensive education effort about the importance of clinical trials, including the fact that such trials can lead to more effective and less costly treatments.

The Maryland legislation requires funding only for clinical trials approved by one of the National Institutes of Health (NIH) or an NIH-sponsored cooperative group or center, the federal Department of Veterans Affairs, or the Food and Drug Administration, and trials conducted by academic medical centers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Related Content